Print Preview Area

Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data
Therapeutics and Clinical Risk Management, 06/26/2012

Bloomgren G et al. – Results from this evaluation provide no evidence of an increased risk of malignancy with intramuscular IFN(beta)–1a use.

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Medical Student Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?

Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data Therapeutics and Clinical Risk Management, 06/26/2012

Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data
Therapeutics and Clinical Risk Management, 06/26/2012